FDA Approves Mitapivat for Anemia in Thalassemia Patients 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
Indonesia Stocks Face Fragile Sentiment After MSCI Warning and Market Rout 
Pfizer Inc.’s planned delivery of critical new medicines, such as respiratory syncytial virus (RSV) vaccine, to low-income nations, is likely to be delayed by several years due to several issues.
According to global health officials, Pfizer has not yet taken some of the necessary actions to make the vaccine accessible in developing nations.
They include getting the shot approved by the WHO and by nonprofit organizations that finance purchases in low-income countries, such as the global vaccine alliance Gavi.
Furthermore, the health agency prefers syringes that are automatically disabled after one injection for safety reasons to prevent reuse, but Pfizer's RSV vaccine is not made for those syringes.
Additionally, the RSV shot is only presently offered in single-dose vials. Multi-dose vials are frequently utilized in situations with less resources since they are less expensive and easier to distribute.
Preservatives must be added to multi-dose vials, therefore the manufacturer must do further tests to make sure there will be no impact on the vaccine's safety or effectiveness.
The vaccine will need a different delivery system to be used in developing countries in Africa and Asia, including alternative packaging and syringes.
Preparations for those modifications are just beginning, according to the World Health Organization.
Pfizer committed to more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere.
The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the RSV vaccine in poorer countries, where RSV, a common cold-like virus, is much more likely to be lethal for very young children.
Pfizer's maternal RSV vaccine is expected to be approved for use in pregnant women in August in the US and several months later in Europe. Its peak sales forecast is more than $2 billion annually, together with the maternal vaccine and an RSV shot for older adults.
